Renowned for his exceptional contributions to myeloma research, Dr. S. Vincent Rajkumar has received a prestigious appointment as the chairman-elect of the Board of Directors for the International Myeloma Foundation (IMF). This appointment comes as Brian G.M. Durie, the current chairman and co-founder of IMF, announces his decision not to seek re-election after serving admirably in the position for 33 years. Dr. Durie will continue to be an esteemed member of the Board, taking on the role of Chairman Emeritus and maintaining his current responsibilities.
Dr. Rajkumar’s influence in the field of myeloma research has been remarkable. He has served as the principal investigator in numerous pivotal clinical trials, leading to the regulatory approval of significant treatments like thalidomide for myeloma in the United States. His profound expertise is well-documented through the publication of over 480 peer-reviewed papers, primarily focusing on multiple myeloma and related plasma cell disorders.
The recipient of prestigious awards, including the Jan Waldenstrom Lifetime Achievement Award (2021), the Mayo Clinic Distinguished Investigator Award (2018), and the Robert A. Kyle Lifetime Achievement Award (2016), Dr. Rajkumar’s dedication and commitment to advancing myeloma research have garnered widespread recognition.
Multiple myeloma is a form of cancer that affects bone marrow plasma cells, a type of white blood cell responsible for producing antibodies. These cancerous plasma cells, known as myeloma cells, often grow in multiple patches or areas within the bones, leading to tumors and areas of bone loss. The disease primarily impacts bone marrow-active areas, such as the spine, skull, pelvis, rib cage, shoulders, and hips in adults.
Founded in 1999, the International Myeloma Foundation (IMF) holds the distinction of being the first and largest global foundation dedicated solely to multiple myeloma. With a vast network of over 525,000 members spread across 140 countries, the IMF continues to play a pivotal role in advancing research, awareness, and support for individuals affected by this complex disease.